Effect of tamoxifen on serum IL-18, vascular endothelial growth factor and nitric oxide activities in breast carcinoma patients
Effect of tamoxifen on serum IL-18, vascular endothelial growth factor and nitric oxide activities in breast carcinoma patients
复制标题
DOI：
10.1111/j.1365-2249.2004.02579.x
复制
发表时间：
2004-09-01
影响因子：
4.6
通讯作者：
Cihan, A
中科院分区：
文献类型：
--
作者：
Coskun, U;Gunel, N;Cihan, A
血管内皮生长因子(VEGF)是一种多功能细胞因子，已被认为是乳腺癌的主要血管生成因子。一氧化氮(NO)是一种强有力的生物分子，参与了肿瘤发生的多步骤过程。白介素18已被证明具有强大的抗肿瘤作用。本研究探讨三苯氧胺治疗对乳腺癌患者血清血管内皮生长因子、一氧化氮和IL-18活性的影响。检测34例绝经后乳腺癌患者三苯氧胺治疗前和治疗3个月后血清血管内皮生长因子、硝酸盐+亚硝酸盐和IL-18水平。他莫昔芬治疗后血清血管内皮生长因子和IL-18水平均下降(P=0.051.0 5，P<0.0 5)。有子宫内膜增厚的患者治疗后血清VEGF水平升高，而无内膜增厚的患者治疗后血清VEGF水平显著降低(P<；0.05)。治疗后血清硝酸盐+亚硝酸盐水平升高，但无统计学意义(P>；0.05)。他莫昔芬治疗后血清中血管内皮生长因子水平的降低可能反映了无内膜增厚的患者血管生成活性降低。三苯氧胺治疗对IL-18的负面影响可能与其通过诱导NO和作为反馈机制的血管内皮生长因子活性降低而抑制肿瘤生长有关。
Vascular endothelial growth factor (VEGF) is a multi-functional cytokine that has been suggested to be a major angiogenic factor in breast cancer. Nitric oxide (NO) is a potent biological molecule that partipicates in the multi-step process of carcinogenesis. Interleukin (IL)-18 has been shown to have potent anti-tumour effects. In this study, we investigated the effect of tamoxifen therapy on serum VEGF, NO and IL-18 activity in breast cancer patients. Serum levels of VEGF, nitrate + nitrite and IL-18 were measured in 34 postmenopausal breast cancer patients before and 3 months after the tamoxifen therapy. Both serum VEGF and IL-18 levels decreased after tamoxifen therapy (P = 0.051, P < 0.05, respectively). Serum VEGF levels increased in patients with endometrial thickness, while patients without endometrial thickness had a significant reduction in serum VEGF levels after therapy (P < 0.05). Serum nitrate + nitrite levels increased after the therapy, but this was not statistically significant (P > 0.05). A decrease in serum VEGF levels with tamoxifen therapy may be a reflection of reduced angiogenic activity in patients without endometrial thickness. The negative effect of tamoxifen therapy on IL-18, which is known to have a potent antitumour activity, may be related to the decreased tumour growth by induction of NO and reduction of VEGF activity as a feedback mechanism.